IPH2201
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for IPH2201, covering 2017-01-04 to 2019-12-17. Get the full timeline:
Most recent: Clinical Trial Update: Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL [Phase 1, Phase 2]